title: Prevention of cerebral ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats.
abstract: Inhibition of phosphodiesterase-4 (PDE4) by rolipram, a prototypical PDE4 inhibitor, reverses memory impairment produced pharmacologically or genetically. Comparably, much less is known about the effect of rolipram on cerebral ischemia-induced memory deficits. The objective of this study was to determine the effects of rolipram on ischemia-induced memory deficit, neuronal damage, and alteration of PDE4 activity in the hippocampus. Memory was examined using Morris water-maze and step-through passive avoidance tests in rats subjected to global cerebral ischemia with or without repeated treatment with rolipram (0.3 or 1 mg/kg, i.p.); neuronal damage in the hippocampus and PDE4 activity in hippocampal tissues were determined using Nissl staining and HPLC, respectively. In the water-maze test, cerebral ischemia significantly increased the escape latency to reach the platform during acquisition training and decreased the exploration time in the target quadrant in the probe trial test; these were blocked by rolipram in a dose-dependent manner. Rolipram also reduced the distracted platform searches induced by cerebral ischemia. In the passive avoidance test, ischemia decreased the 24-h latency to the dark compartment, which was also blocked by rolipram treatment. In addition, Nissl staining revealed ischemia-induced neuron loss in hippocampal CA1; this was blocked by rolipram. Further, cerebral ischemia led to increases in activity of PDE, primarily PDE4, in the hippocampus, which also was antagonized by rolipram. These results suggest that rolipram prevents cerebral ischemia-induced memory deficits via inhibition of increased PDE4 activity and attenuation of hippocampal, neuronal damages induced by ischemia. PDE4 may be a target for treatment of cognitive disorders associated with cerebral ischemia.
authors.affiliation: Department of Pharmacology, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, People's Republic of China.
authors.forename: Ling-Xia
authors.initials: LX
authors.lastname: Li
authors.forename: Yu-Fang
authors.initials: YF
authors.lastname: Cheng
authors.forename: Huan-Bing
authors.initials: HB
authors.lastname: Lin
authors.forename: Chuang
authors.initials: C
authors.lastname: Wang
authors.forename: Jiang-Ping
authors.initials: JP
authors.lastname: Xu
authors.forename: Han-Ting
authors.initials: HT
authors.lastname: Zhang
mesh_terms: D000818:Animals; D002545:Brain Ischemia / Q000150:complications*; D056547:CA1 Region, Hippocampal / Q000187:drug effects / Q000473:pathology; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4 / Q000378:metabolism; D008297:Male; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D008569:Memory Disorders / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D009410:Nerve Degeneration / Q000473:pathology*; D009474:Neurons / Q000187:drug effects / Q000473:pathology; D058988:Phosphodiesterase 4 Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D020889:Rolipram / Q000494:pharmacology*
chemical_list: D058988:Phosphodiesterase 4 Inhibitors; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020889:Rolipram